DISCOVER MAGNEXFLO

The new automatic filtration system by BEA Technologies that supports sustainable development in the pharmaceutical sector 

Nowadays, promoting economic circularity is key, regardless of the industry domain. The Italian company, one of the European leaders in filtration technologies, is highly committed to study innovative filtration solutions for challenging new applications.


In the context of economic circularity and sustainability, BEA Technologies research is oriented to the creation of innovative filtration solutions, to promote operational efficiency, reducing energy consumption and processing with limited waste.


In particular, in the field of filtration of critical products for the pharmaceutical sector, BEA Technologies has created MAGNEXFLO an innovative, green solution that is suitable for solving a wide range of specific filtration problems. This system is extremely versatile and allows numerous customizations based on the most specific needs.

MAGNEXFLO can be castor-mounted for full mobility and operational flexibility

The Italian company, therefore, responds to the demands of the pharmaceutical sector, and is among the most innovative companies, entering the context of the new current challenges: "We are currently studying green products, specific for pharmaceutical applications", declares Roberto Bea, President of BEA Technologies, who considers Research and Development as the key to success. “Our goal is to become the European reference leader in providing innovative filtration products for this sector; our efforts are dedicated to consolidating our position as a significant global player, without losing sight of the need for a radical renewal of our economic model, aiming at circularity.”

The purification of gels for pharmaceutical use and liquids with a viscosity higher than that of aqueous solutions represents a problem in drug production systems and in filling glass containers, where low flow speeds associated with sterile filtration of more viscous products are slowing down production processes (especially if depyrogenation and sterilisation filtration are required).


The purification of gels for use in the pharmaceutical, cosmetic and medical sectors is a challenge, especially if it is necessary to guarantee very low final endotoxin content. The gels are highly biocompatible and serve to coat the active ingredients, to allow a controlled release and increase the assimilable quantity of a specific drug. Recently endotoxin-free purified gels have also become important in stabilizing vaccines and other sensitive formulations, to reduce risks of secondary reactions for improved patient safety.


These issues demand purpose-designed equipment, and BEA’s MAGNEXFLO with its high capacity and automatic filtration technology perfectly responds to this call.

MAGNEXFLO by BEA Technologies is a fully automated and stand-alone filtration system for clarifying viscous gels and solutions

All BEA Technologies activities are regulated by the Quality Management Manual for the design, production and distribution, and after-sales service phases. The Quality Management System is certified by an international body and recognized according to the ISO 9001 and ISO 3834 standards.


Thanks to this new line of automatic regenerable filters, the Italian company fits into the international commitment to sustainability and continues in the pursuit of its mission: to design filter elements and high-tech filtration systems capable of satisfying the growing requirements of the production, through the continuous improvement of processes and performances.


Discover more on www.bea-italy.com

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: MyonexGo to article: Controlant Company InsightGo to article: ControlantGo to article: SHL MedicalGo to article: LabcorpGo to article: ReutersGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: TQS Integration Company InsightGo to article: TQS IntergrationGo to article: Biesterfeld Go to article: CommentGo to article: Biotech and China: a global opportunityGo to article: Intranasal ketamine could effectively treat phantom painGo to article: EU biosimilar wave slows as biosimilar approvals decrease in the EUGo to article: Biosynth Carbosynth Company InsightGo to article: Biosynth CarbosynthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: SkyepharmaGo to article: In DepthGo to article: Unpacking the complex challenge of biologicsGo to article: Living medicines: using bacteria to fight cancerGo to article: The marred history of HIV vaccine trialsGo to article: Has Covid-19 exposed the weakness of the US pharma supply chain?Go to article: How the pandemic pushed pharmacovigilance to innovateGo to article: ExeVir: the llama-derived antibody that could fight Covid-19Go to article: BEA TechnologiesGo to article: WatlowGo to article: DuojectGo to article: ButterworthGo to article: In DataGo to article: Data: Big Data hiring efforts in pharmaGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue